Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma.

Br J Cancer · 2026 · PMC13184113 · PMID 41917212

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

borderline significantp = 0.054so close (0.05 < p ≤ 0.1)

Subgroup analyses revealed that patients with higher pre-treatment cfEBV DNA levels who received three IC cycles achieved a borderline significant PFS advantage ( p = 0.054).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.